Selecting short length nucleic acids localized in exosomes improves plasma EGFR mutation detection in NSCLC patients

Table 2 Comparison between cfDNA and short-length exosomal nucleic acids

Sample^a	Target	Mutant events	Wild-type events	Fraction (%)	Mutant allele ratio		Wild-type allele ratio
Sample^a	Target	Mutant events	Wild-type events	Fraction (%)	exoDNA/cfDNA	exoTNA/cfDNA	exoDNA/cfDNA	exoTNA/cfDNA
Spiked sample 1 (Ex19del)	cfDNA	20	418	4.78	0.5	1.2	0.6	2.7
	Short-length-exoDNA	9	270	3.33
	Short-length-exoTNA	24	1138	2.11
Spiked sample 2 (L858R)	cfDNA	1	156	0.64	1	2	0.8	2.6
	Short-length-exoDNA	1	131	0.76
	Short-length-exoTNA	2	399	0.5
Spiked sample 3 (L858R)	cfDNA	2	38	5.26	0	2.5	0	6
	Short-length-exoDNA	0	1	0
	Short-length-exoTNA	5	228	2.19
Spiked sample 3 (T790M)	cfDNA	0	97	0	N.A.	N.A.	N.A.	N.A.
	Short-length-exoDNA	6	89	6.74
	Short-length-exoTNA	8	307	2.61

cfDNA cell-free DNA, exoDNA exosomal DNA, exoTNA exosomal DNA and RNA, Ex19del exon 19 deletion, N.A not available
^aSpiked samples with pooled plasma from patients harboring mutations in EGFR (Ex19del, L858R, and T790M). cfDNA and short-length exoDNA were extracted using MagMAX Cell-Free DNA Isolation Kit. Short-length exoTNA was extracted using MagMAX™ Total Nucleic Acid Isolation Kit

ISSN: 1475-2867